Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07323654 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of KT-621 Administered Orally to Adult Participants With Moderate to Severe Eosinophilic Asthma

Study acronym: BREADTH
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial sites expanded: 71 → 81 locations Eligibility criteria expanded, about 21 words Show 1 more changeShow less
    • Eligibility criteria expanded, about 21 words
  2. Trial sites expanded: 58 → 71 locationsv7
  3. Trial sites expanded: 27 → 58 locationsv6
  4. Trial sites expanded: 17 → 27 locationsv5
  5. Trial sites expanded: 9 → 17 locationsv4
Show 2 earlier versionsHide 2 earlier versions
  1. Study sites: 5 to 9v3
  2. Study sites: 2 to 5 Start date changed from estimate of Mar 2026 to Jan 28, 2026v2 Show 1 more changeShow less
    • Start date changed from estimate of Mar 2026 to Jan 28, 2026
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This Phase 2b study is designed to evaluate the safety and efficacy of KT-621 in participants with uncontrolled moderate to severe eosinophilic asthma. The main goals of this study are to investigate how effective KT-621 is at treating uncontrolled moderate to severe eosinophilic asthma, the safety and tolerability of KT-621, and how KT-621 behaves in the body.
Trial Details
NCT Number NCT07323654
Lead Sponsor Kymera Therapeutics, Inc.
Conditions Eosinophilic Asthma
Enrollment 264 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov